Sunday, June 6, 2010 | Oncolink

Oncolink Features

Find My Cancer Drug

A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results Presenter: T. I. Yock, Massachusetts General Hospital, Boston, MA; Children's Hospital Medical Center, Boston, MA; Harvard Medical School, Boston, MA Background Medulloblastoma (MB) is the most common malignant brain tumor occurring in...
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma Presenter: Steven O'Day, The Angeles Clinic and Research Institute, Los Angeles, CA. Background Advanced melanoma (Stage III/IV) has an increasing global incidence. Many patients are diagnosed at a relatively young age, and the disease carries...
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) Presenter: Y. Bang, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Background Efficacy of conventional chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) appeared to reach a...
Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients Presenter: S. H. Giordano, University of Texas M. D. Anderson Cancer Center, Houston, TX Background Diabetes and obesity are very prevalent in the US population and the incidence of these disorders continues to rise. The National...
Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer Background In locally advanced prostate cancer, the combination of radiation therapy (RT) and androgen deprivation therapy (ADT) has been demonstrated to provide superior outcomes when compared to RT or ADT alone (Bolla, Lancet, 2002). ...
Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study Presenter: M. T. Milano, Department of Radiation Oncology, University of Rochester, Rochester, NY Background Second malignant neoplasms are the leading cause of death among long-term survivors of Hodgkin lymphoma (HL) (Hoppe et al. Ann Oncol,...
Neurocognitive outcomes after proton radiation for pediatric brain tumors Presenter: M. B. Pulsifer, Massachusetts General Hospital, Boston, MA; Children's Hospital Medical Center, Boston, MA; Harvard Medical School, Boston, MA Background Pediatric brain tumors account for 20% of all pediatric cancers, and treatment...
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group (GOG) study Presenter: Robert Burger, MD for the Gynecologic Oncology Group and Fox Chase Cancer Center, Philadelphia, PA Background Ovarian cancer is the most common gynecologic cancer, and is the 4th leading cause of cancer death in women. ...
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) Presenter: E. A. Quoix, on behalf of IFCT; Hôpitaux Universitaires, Strasbourg, France Background Lung cancer is the most common cause of cancer mortality in the US, accounting for 30% of cancer-related deaths in men and 26% of cancer-related...